Lexicon announced that Express Scripts has determined that it will place Inpefa on its Premier Access and Premier Performance national formularies for Medicare patients on November 1, 2023. This placement will provide access to Inpefa for Express Scripts Medicare patients in plans that utilize these formularies and who meet the parameters of Inpefa’s FDA-approved indication.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on LXRX:
- INPEFA® (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients
- Lexicon appoints Tom Garner as SVP, CCO
- Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
- Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023
- Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference